Filippo Petralia
About Filippo Petralia
Filippo Petralia serves as the Associate Director of Strategic Planning and Analytics at Travere Therapeutics in San Diego, California. With a strong background in pricing strategies and competitive intelligence, he has over a decade of experience in the biotechnology and pharmaceutical sectors.
Work at Travere Therapeutics
Filippo Petralia has been serving as the Associate Director of Strategic Planning and Analytics at Travere Therapeutics since 2021. In this role, he is based in San Diego, California, where he focuses on strategic planning initiatives and analytics within the biotechnology sector. His responsibilities include developing and implementing strategies that support the company's objectives in the pharmaceutical market.
Education and Expertise
Filippo Petralia holds an MBA from the Rady School of Management at the University of California, San Diego, which he completed from 2007 to 2009. He also earned a Master's degree in Molecular Immunopathology and a Bachelor's degree in Biotechnologies from Università degli Studi di Milano-Bicocca. His educational background provides him with a strong foundation in both management and scientific principles relevant to the biotechnology and pharmaceutical industries.
Background
Filippo Petralia has a diverse professional background that spans various roles in the biotechnology and pharmaceutical sectors. He has worked in strategic planning, competitive intelligence, and commercial strategy development. His previous positions include roles at Alkermes, Takeda, and PriceSpective, where he gained significant experience in pricing and reimbursement strategies, as well as financial modeling and forecasting.
Achievements
Throughout his career, Filippo Petralia has developed commercial strategies for pharmaceutical products at various stages of their life cycle. He has demonstrated proficiency in financial modeling and forecasting, which are essential skills for his current role in strategic planning and analytics. Additionally, he holds securities licenses of Series 79 & 63, indicating his expertise in investment banking and financial advisory roles.